Boehringer Ingelheim's pololike kinase inhibitor volasertib won breakthrough-therapy designation from the FDA as a potential treatment for acute myeloid leukemia. The approval was based on data from a midstage trial that showed volasertib, in combination with low-dose cytarabine, improved overall and event-free survival compared with cytarabine alone.
Boehringer's leukemia candidate wins breakthrough status from FDA
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.